Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma

• Prif Awduron: Yujin Zhao (Awdur), Chang Huang (Awdur), Zhutian Zhang (Awdur), Jiaxu Hong (Awdur), Jianjiang Xu (Awdur), Xinghuai Sun (Awdur), Jianguo Sun (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Glaucoma is the leading cause of irreversible vision loss worldwide, and reduction of intraocular pressure (IOP) is the only factor that can be interfered to delay disease progression. As the first line and preferred method to treat glaucoma, eye drops have many shortcomings, such as low bioavailabi...